International Headache Academy 2026 Event Recap
The 2026 International Headache Academy (IHA) was held from February 26-28, at the UCLA Meyer and Renee Luskin Conference Center in Los Angeles, California. The program brought together 55 delegates from 22 states, three provinces/districts, and three countries, resulting in a diverse group of early-career clinicians and researchers in headache medicine.
The International Headache Academy is designed to inspire a long-term commitment to headache medicine in young neurologists and research scientists through an educational program focusing on clinical and research aspects of the field. The program offers exposure to a wide range of opportunities in both the clinical and research sides of headache medicine, with instruction from leading experts across topics such as pathophysiology, diagnosis, treatment, and patient education. Over the course of this year’s event, participants engaged closely with faculty and peers, contributing to an environment that encouraged thoughtful discussion, collaboration, and professional growth.
A Collaborative Learning Experience
A defining aspect of the IHA is how participants actively shape the experience. Rather than just observing from the sidelines, attendees contribute through clinical perspectives, research, and discussion. Throughout the program, 19 delegates presented clinical cases, participated in structured debates, and shared their research, bringing real-world perspectives into each session. The program was further strengthened by the presence of the current AHS President and several past presidents, who were actively involved in discussions and shared their expertise.
Highlights: From AI Debates to Emerging Migraine Treatments
Several moments throughout the weekend stood out. The session on Friday morning, “Debate: Artificial Intelligence”, moderated by Chia-Chun Chiang, MD, sparked meaningful discussion about how emerging technologies may shape diagnosis and treatment, while also highlighting their limitations. The debate encouraged a range of perspectives and set the tone for conversation across the program.
Another key moment came during “Special Session: What is the Most Promising Emerging Target for Migraine Treatment?” where Peter J. Goadsby, MD, PhD, FAHS and Andrew Charles MD, FAHS, explored emerging therapeutic targets, including PACAP and TRPM8. The discussion pointed toward a future in which clinicians may have access to a broader range of migraine-targeted therapies beyond CGRP, offering renewed optimism for both providers and patients.
Breakout sessions gave attendees a chance to connect in smaller groups, making it easier to talk through ideas and engage directly with faculty. Some of the conversations covered clinical research, basic science, education, advocacy, and practice management, with added perspective from current and past AHS leadership.
The IHA also recognized outstanding research contributions. Bradley Ong, MD, was selected as the recipient of the 2026 IHA Research Award for his presentation on Hormonal exposures during in vitro fertilization and their impact on migraine activity. His work reflected the type of innovative thinking that continues to move the field forward.
Networking opportunities were woven throughout the program, allowing attendees to build connections in both formal and informal settings. Whether during discussions, shared meals, or between sessions, these interactions helped foster a sense of community that extends beyond the IHA itself.
The Lasting Impact of IHA 2026
The 2026 IHA brought together a group of clinicians and researchers committed to advancing headache medicine through collaboration, learning, and innovation. Throughout the program, conversations highlighted the need to combine clinical expertise with a patient-centered approach, recognizing that many patients have already been through a long and difficult journey.
At the same time, discussions highlighted the continued evolution of the field, from the growing role of artificial intelligence to the development of new therapeutic pathways that are shaping more personalized approaches to care. These discussions, along with the connections formed during the program, will continue to influence both clinical practice and research in the years ahead.
With the next International Headache Academy expected in early 2027 and ongoing opportunities for engagement through the American Headache Society, participants are encouraged to stay connected and reach out with any questions.